Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials by Mark Nelson, Andrew Hill, Yvon van Delft, Christiane Moecklinghoff

Get full text

Framingham Risk Score Prediction at 12 Months in the STANDFIRM Randomized Control Trial by Thanh G. Phan, Velandai K. Srikanth, Dominique A. Cadilhac, Mark Nelson, Joosup Kim, Muideen T. Olaiya, Sharyn M. Fitzgerald, Christopher Bladin, Richard Gerraty, Henry Ma, Amanda G. Thrift

Get full text

Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. by Huw Price, Loveleen Bansi, Caroline A Sabin, Sanjay Bhagani, Andrew Burroughs, David Chadwick, David Dunn, Martin Fisher, Janice Main, Mark Nelson, Deenan Pillay, Alison Rodger, Chris Taylor, Richard Gilson, UK Collaborative HIV Cohort Hepatitis Group, Steering Committee

Get full text

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (ST... by Rory Wolfe, Christopher M Reid, Andrew Tonkin, John J McNeil, Mark Nelson, Sophia Zoungas, Stephanie A Ward, Stephen J Nicholls, Geoffrey Cloud, Ingrid Hopper, Andrea Curtis, Joanne Ryan, Lawrence Beilin, Anthony Wierzbicki, Simone Spark, Trevor T-J Chong, Alissia Kost

Get full text

Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus. by Aminata Sy, Leanne McCabe, Emma Hudson, Azim M Ansari, Vincent Pedergnana, Shang-Kuan Lin, S Santana, Marzia Fiorino, Aftab Ala, Ben Stone, M Smith, Mark Nelson, Stephen T Barclay, Stuart McPherson, Stephen D Ryder, Jane Collier, Eleanor Barnes, Ann Sarah Walker, Sarah L Pett, Graham Cooke, STOP-HCV-1 trial team

Get full text